Innovative Medicines Initiative

From Wikipedia, the free encyclopedia

The Innovative Medicines Initiative (IMI) is a European Seventh Framework Programme initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (Public-Private Partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks.